New drug BI 3821001: first safety tests in healthy volunteers begin
NCT ID NCT07526194
First seen Apr 14, 2026 · Last updated Apr 28, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called BI 3821001 in healthy men aged 18 to 55. The main goal is to see if it is safe and how the body processes it. Participants receive either a single dose of the drug or a placebo. No direct health benefit is expected, but the results will guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.